Latest news with #Senzime
Yahoo
26-05-2025
- Business
- Yahoo
Senzime Applauds Announcement of Upcoming European Pediatric Guidelines of Neuromuscular Monitoring
UPPSALA, SE / / May 26, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Lisbon, Portugal - Senzime AB (publ.) welcomes today's pre-announcement of the first pediatric guidelines of quantitative neuromuscular monitoring during anesthesia. The guideline announcement was done at the Euroanaesthesia 2025 (ESAIC) congress in Lisbon with final publication and announcement expected later in 2025, representing a significant update to pediatric anesthesia practice. "Pediatric patients have long been underserved when it comes to neuromuscular monitoring," commented Philip Siberg, CEO of Senzime. "Today's announcements are based on analysis of over 8,000 studies signaling EMG as a recommended monitoring technology in pediatric anesthesia. This represents a pivotal moment for clinicians who want to ensure safety and recovery in the youngest and most vulnerable patients. The announcement further represents a critical step in improving patient safety and presents a substantial market opportunity for our TetraGraph system, a leading EMG-based quantitative train-of-four (TOF) solution."Each year, approximately 10-12 million pediatric major surgeries are performed worldwide with neuromuscular blocking drugs, with around 3 million in the US alone. Research has shown that without proper monitoring, over 40% of pediatric patients experience residual neuromuscular block (rNMB) postoperatively, leading to respiratory complications, airway obstruction, and delayed the well-documented risks of rNMB, pediatric anesthesia has historically relied on qualitative neuromuscular monitoring or no monitoring at all, due to the lack of specialized pediatric solutions. The pre-announced guidelines call for a recommendation of quantitative neuromuscular monitoring, ensuring that paralytic and reversal drugs are properly dosed, and rNMB is TetraGraph® system is the only neuromuscular monitor on the market with a separate and specific FDA-cleared electromyography (EMG) sensor for use on patients from one month old. Unlike legacy neuromuscular monitors, TetraGraph monitors use EMG to accurately analyze the direct effects of paralytic drugs and does not require free-moving muscles, making it ideal for pediatric and tucked-arm cases such as robotic surgical procedures. For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: About Senzime Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at Attachments Senzime applauds announcement of upcoming European pediatric guidelines of neuromuscular monitoring SOURCE: Senzime View the original press release on ACCESS Newswire
Yahoo
19-05-2025
- Business
- Yahoo
BULLETIN from Annual General Meeting in Senzime AB (publ)
UPPSALA, SE / / May 19, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - The annual general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the "Company") was held on 19 May 2025 at the Company's premises on Verkstadsgatan 8, Uppsala, whereby the shareholders primarily resolved on the following matters. Annual report and results The annual general meeting adopted the income statement and the balance sheet for the financial year 2024 and resolved, in accordance with the board of directors' proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid. Discharge from liability The general meeting granted the members of the board of directors and the managing director discharge from liability for the management of the Company's business for the financial year 2024. Remuneration to the board of directors and the auditor The annual general meeting resolved that the remuneration to the board of directors shall be SEK 1,100,000 to the chairman, SEK 375,000 to the vice chairman, SEK 550,000 to the other members of the board, and SEK 275,000 to members who are not independent from the Segulah group. In accordance with the proposal presented, directors who are independent of the Craafoord family and the Segulah group are encouraged to invest 50 percent of the remuneration (after tax) in shares in the Company by purchasing shares on the market. The annual general meeting resolved that no board remuneration shall be paid to a board member who during the fiscal year 2025 receives consultancy fees from the Company exceeding a total amount equivalent to twice the cash board remuneration resolved at this annual general meeting. Furthermore, the annual general meeting resolved that remuneration shall be paid to the audit committee with SEK 75,000 to the chairman and SEK 37,500 to the other members, to the remuneration committee with SEK 50,000 to the chairman and SEK 25,000 to the other members, and to the R&D committee with SEK 50,000 to the chairman and SEK 25,000 to the other members. The annual general meeting resolved that remuneration to the auditor would be paid according to approved invoices. Election of board of directors and auditor The annual general meeting resolved that the board of directors should consist of six (6) directors without any deputy directors. The general meeting resolved, for the time until the end of the next annual general meeting, to re-elect Per Wold-Olsen, Adam Dahlberg, Sorin Brull, Göran Brorsson and Lars Axelsson and elect Ann Costello as members of the board of directors. Per Wold-Olsen was re-elected as the chairman of the board of director and Adam Dahlberg was re-elected as vice chairman. It was resolved to re-elect PricewaterhouseCoopers AB as auditor for the time until the end of the next annual general meeting. Nomination committee for the annual general meeting 2026 The annual general meeting resolved that the Company, in advance of the annual general meeting in 2026, shall establish a nomination committee. The nomination committee shall be appointed by instruction from the chairman of the board of directors to the three largest shareholders in the Company on 1 September 2025 to appoint a representative each. Adoption of guidelines for remuneration to the senior management The annual general meeting resolved, in accordance with the board of directors' proposal, to adopt new guidelines for remuneration to the senior management. Articles of association The annual general meeting resolved to amend the articles of association by adjusting the limits for the share capital and the number of shares. Adoption of incentive program 2025/2029The annual general meeting resolved, in accordance with the board's proposal, to introduce an employee stock option program 2025/2029 for employees and key individuals in the Company or the Company's group through a directed issue of warrants to the Company and approval of the transfer of warrants and shares in the company to participants in the employee stock option program. The employee stock option program 2025/2029 includes a maximum of 1,650,000 employee stock options. Authorization for other issues The annual general meeting authorized the board of directors, for the time until the next annual general meeting, whether on one or several occasions, to increase the Company's share capital with no more than twenty (20) percent of the total share capital in the Company when the authorization is utilized for the first time. The board of directors shall be able to resolve on issues of shares, warrants and/or convertible instruments with or without deviation from the shareholders' pre-emption rights and/or by an issue in kind or by way of set-off or other conditions as referred to in the Swedish Companies act. The board of directors shall have the right to determine the terms and conditions for issues under this authorization and who shall have the right to subscribe for the instruments issued. The terms shall be in accordance with market terms. It was noted, however, that the proposal for a shareholder program for the board of directors, presented in the notice did not receive the required majority (nine-tenths of both the votes cast and the shares represented at the meeting), resulting in the proposal not being adopted. For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Slavoljub Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: About Senzime Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany. Headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at Attachments BULLETIN from annual general meeting in Senzime AB (publ) SOURCE: Senzime View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Senzime Launches Medical Affairs Division and Education Platform to Drive Transformation in Anesthesia Monitoring
UPPSALA, Sweden and ST. LOUIS, May 13, 2025 /PRNewswire/ -- Senzime, a global leader in precision-based perioperative monitoring solutions, today announced the formation of a new Medical Affairs division and the parallel launch of Senzime Academy—an open-access education platform designed to advance the implementation of guideline-supported neuromuscular monitoring worldwide. "These initiatives aim to drive the next wave of clinical transformation in anesthesia care, as Senzime continues to strengthen our role not only as a device innovator, but as a scientific and educational partner," said Philip Siberg, CEO of Senzime. "Our new Medical Affairs team and educational platform reflect our commitment to partnering with providers to implement evidence-based practices that elevate patient outcomes." Building a Global Clinical CommunitySenzime's new Medical Affairs division will serve as a hub for collaboration with leading academic centers, anesthesia providers, and perioperative teams. Its mission is to translate clinical research into real-world practice, support best-in-class implementation, and elevate global awareness about the ongoing risks of residual neuromuscular block (rNMB). The division is led by Jen Sanders, Director of Clinical and Medical Affairs. Addressing the Real-World Needs of Anesthesia TeamsTo support widespread adoption of neuromuscular monitoring, Senzime Academy offers clinicians on-demand training on quantitative train-of-four (TOF) monitoring and best practices for TetraGraph® use. The digital platform includes video modules, clinical case examples, and implementation guides for both adult and pediatric care settings. Built on 40+ Years of Scientific ResearchSenzime's flagship TetraGraph system is the result of over four decades of neuromuscular monitoring research, translated into a clinically robust, EMG-based platform purpose-built to meet the demands of modern surgery. Its proprietary TOF monitoring technology is clinically evaluated in 19 peer-reviewed publications, making it the most studied EMG system available today. TetraGraph is used in over 3,500 operating rooms worldwide, supporting compliance with best practices outlined by the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology and Intensive Care (ESAIC). More information how Senzime's solutions can be used across specialized clinical applications, such as robotic-assisted surgeries, pediatrics, and enhanced recovery after surgery (ERAS), is available at More information about Senzime Academy is available at For further information, please contact:Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: About SenzimeSenzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at View original content to download multimedia: SOURCE Senzime Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Senzime Publishes Annual and Sustainability Report for 2024
UPPSALA, SWEDEN / / April 24, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) announces today that the company's annual and sustainability report for 2024 is published and available at the website "2024 was a year of high growth, successful product launches, publication of favorable clinical studies, and continued commercial expansion.", commented Philip Siberg, CEO of Senzime For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Slavoljub Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: About Senzime Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany. Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at This information is information that Senzime is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 15:30 CEST. Attachments Annual Report 2024 SOURCE: Senzime View the original press release on ACCESS Newswire
Yahoo
22-04-2025
- Business
- Yahoo
Interim Report January-March 2025: 94 Percent Growth
UPPSALA, SE / / April 22, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime AB's (publ) interim report for January - March 2025 is now available on the company's website Financial information January - March 2025 Net sales amounted to TSEK 23,499 KSEK (12,120), a 94 percent increase. Sales of instruments/other were TSEK 9,237 (4,864), a 90 percent increase. Sales of disposables were TSEK 14,262 (7,256), a 97 percent increase. The gross margin excluding amortization was 65.9 percent (64.3). Operating expenses amounted to TSEK 37,297 (37,441) EBITDA was TSEK -20,839 (-28,546). Profit (loss) after financial items was TSEK -35,522 (-28,719). Earnings per-share were SEK -0.27 (-0.23). Cash and cash equivalents as of March 31, 2025, were TSEK 62,059 (116,856). CEO comment:We have strong momentum. Net sales in Q1 increased by 94 percent to SEK 23.5 million. A quarter with record sales, several new important hospital contracts, product launches, and expansion to meet demand. Deliveries of disposable sensors more than doubled once again. Our new TetraGraph system, introduced in the US during the fourth quarter of 2024, has been very well received by the market. Numerous clinical evaluations conducted at hospitals in the US and Europe have unanimously praised its unique design and how it simplifies and accelerates compliance with the new clinical guidelines for neuromuscular monitoring. During the quarter, we announced several key hospital contracts won through competitive evaluations. This is a direct result of the successful investments we have made in research and development in recent years. In total, we delivered over 440 new TetraGraph systems in the first quarter, compared with just under 900 TetraGraph Classics delivered throughout all of 2024. In mid-March, we also launched the new TetraGraph system in the European market. In just two weeks, we delivered more new systems than we sold TetraGraph Classics in Europe during all of 2024. More launches are planned for the year, with Japan and South Korea next in line. Demand is strong. The success of our business model is especially evident in the sales of disposable sensors, which continue to grow at a triple-digit rate. Utilization of the TetraGraph systems is increasing, and we are continuously winning new customers. The gross margin improved compared to Q1 last year and operating expenses were in line with the previous year despite extensive commercial investments. We will achieve profitability through high utilization of our systems, offer the most user-friendly and innovative solutions, and scale up with the support of smart, industrial partnerships. The pipeline for 2025 is strong, and we continue to see high demand. We have a unique portfolio of solutions that meet market needs. Follow us on our journey toward improved patient safety for millions of patients. Philip Siberg, CEO Uppsala, Sweden, April 2025 For further information, please contact: Philip Siberg, CEO of Senzime ABPhone: +46 (0) 707 90 67 34, e-mail: Slavoljub Grujicic, CFOPhone: +46 (0) 76 306 60 11, e-mail: About Senzime Senzime develops CE- and FDA-cleared precision-based patient monitoring solutions to safeguard patients during anesthesia and recovery. Senzime's TetraGraph® and ExSpiron® 2Xi systems are powered by proprietary, smart algorithms to monitor neuromuscular and respiratory function in real-time during and after surgery. The technologies are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime's products are commercialized in over 30 countries including direct sales teams in US and Germany. Established in 1999 and headquartered in Uppsala, Sweden, Senzime is backed by long-term investors and listed on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the New York OTCQX market (SNZZF). More information is available at . This information is information that Senzime is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-22 08:30 CEST. Attachments Senzime Interim Q1 ENG SOURCE: Senzime View the original press release on ACCESS Newswire Sign in to access your portfolio
